Pilot Study to Determine Therapeutic Response of Pemetrexed (Alimta) in Recurrent or Progressive Primary Central Nervous System Lymphoma (PCNSL) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2011
At a glance
- Drugs Pemetrexed (Primary)
- Indications CNS cancer
- Focus Therapeutic Use
- 24 Feb 2010 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 23 Oct 2008 Planned end date changed from 1 Oct 2010 to 1 May 2012 as reported by ClinicalTrials.gov.
- 23 Oct 2008 Actual start date (Oct 2008) added as reported by ClinicalTrials.gov.